Epigenetics: The New Frontier in Heart Disease Detection

When most people think about their risk for heart disease, they focus on family history and genetics. However, Cardio Diagnostics Holdings (NASDAQ: CDIO) is pioneering a shift toward epigenetics, a field that examines how lifestyle, behavior, and environment influence gene expression without altering DNA. The company’s diagnostic platform leverages the science of epigenetics to uncover hidden cardiovascular risks that traditional genetic tests might miss. According to its CEO, epigenetics not only identifies problems but also offers insights into potential solutions, empowering individuals to take proactive steps for heart health.

Epigenetics reveals which genes are active and to what extent, providing a dynamic snapshot of a person’s health. For example, factors like diet, stress, and exercise can modify epigenetic markers, affecting heart disease risk. Cardio Diagnostics aims to make this information accessible through its tests, helping patients and doctors make informed decisions. The company’s newsroom at https://ibn.fm/CDIO provides the latest updates, and more details can be found in the Read More>> article. MissionIR, a communications platform within the Dynamic Brand Portfolio @ IBN, syndicated this content to enhance visibility for Cardio Diagnostics.

This approach matters because heart disease remains a leading cause of death globally, and traditional risk assessments often overlook epigenetic factors. By integrating epigenetics, Cardio Diagnostics offers a more personalized view of cardiovascular risk, potentially enabling earlier interventions and better outcomes. Investors and patients alike should watch this space as the company continues to develop its platform.